$18.35
0.54%
NYSE, Sep 19, 10:11 pm CET
ISIN
US8816242098
Symbol
TEVA

Teva Pharmaceutical Industries Limited Sponsored ADR Stock price

$18.35
+0.79 4.50% 1M
+2.06 12.65% 6M
-3.69 16.74% YTD
+0.59 3.32% 1Y
+9.68 111.65% 3Y
+9.40 105.03% 5Y
-44.47 70.79% 10Y
-14.67 44.43% 20Y
NYSE, Closing price Fri, Sep 19 2025
-0.10 0.54%
ISIN
US8816242098
Symbol
TEVA
Industry

Key metrics

Basic
Market capitalization
$21.2b
Enterprise Value
$36.2b
Net debt
$15.1b
Cash
$2.2b
Shares outstanding
1.1b
Valuation (TTM | estimate)
P/E
negative | 7.0
P/S
1.3 | 1.2
EV/Sales
2.2 | 2.1
EV/FCF
40.7
P/B
3.1
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$16.6b | $17.2b
EBITDA
$4.8b | $5.0b
EBIT
$3.8b | $4.3b
Net Income
$-158.0m | $3.0b
Free Cash Flow
$890.0m
Growth (TTM | estimate)
Revenue
2.1% | 4.1%
EBITDA
-0.3% | 7.3%
EBIT
1.2% | 19.8%
Net Income
66.8% | 283.8%
Free Cash Flow
31.1%
Margin (TTM | estimate)
Gross
50.9%
EBITDA
28.7% | 29.0%
EBIT
22.6%
Net
-1.0% | 17.5%
Free Cash Flow
5.4%
Financial Health
Equity Ratio
13.7%
Return on Equity
-30.5%
ROCE
13.3%
ROIC
28.1%
Debt/Equity
2.5
More
EPS
$-0.2
FCF per Share
$0.8
Short interest
4.4%
Employees
-
Rev per Employee
-
Show more

Is Teva Pharmaceutical Industries Limited Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,012 stocks worldwide.

Teva Pharmaceutical Industries Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:

3x Hold
33%
6x Sell
67%

Analyst Opinions

9 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:

Hold
33%
Sell
67%

Financial data from Teva Pharmaceutical Industries Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
16,628 16,628
2% 2%
100%
- Direct Costs 8,167 8,167
2% 2%
49%
8,461 8,461
2% 2%
51%
- Selling and Administrative Expenses 3,754 3,754
5% 5%
23%
- Research and Development Expense 978 978
1% 1%
6%
4,779 4,779
0% 0%
29%
- Depreciation and Amortization 1,022 1,022
5% 5%
6%
EBIT (Operating Income) EBIT 3,757 3,757
1% 1%
23%
Net Profit -158 -158
67% 67%
-1%

In millions USD.

Don't miss a Thing! We will send you all news about Teva Pharmaceutical Industries Limited Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Teva Pharmaceutical Industries Limited Sponsored ADR Stock News

Neutral
GlobeNewsWire
one day ago
PARSIPPANY, N.J., and TEL AVIV, Israel, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of 10 posters from its innovative schizophrenia medicines portfolio, including long-term safety data from the completed SOLARIS Phase 3 trial showing no incidence of post-injection deliriu...
Neutral
Business Wire
5 days ago
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Data from the completed phase 3 SOLARIS trial to be presented at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025, in San Diego, California Teva will host a conference call for analysts and investors on Monday, September 22, 2025, at 11:00 am ET to discuss these data To access a live...
Neutral
GlobeNewsWire
5 days ago
TEL AVIV, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025, in San Diego, California.
More Teva Pharmaceutical Industries Limited Sponsored ADR News

Company Profile

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.

Head office Israel
CEO Richard Francis
Founded 1901
Website www.tevapharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today